Bli medlem
Bli medlem

Du är här

2014-04-04

MEDA: Statement by the Board of Directors of Meda

This statement is made by the Board of Directors (the "Board") of Meda
AB (publ) ("Meda") pursuant to the Securities Markets Act and/or the
Financial Instruments Trading act.

The Board hereby confirms that it has been contacted by Mylan, Inc.
("Mylan") regarding an indicative proposal to combine the two
businesses. The Board has convened and has decided to reject the
proposal. All continued discussions between Meda and Mylan have been
terminated without further actions.

The Board of Directors
Meda AB (publ)

For further inquiries, please contact:

Paula Treutiger, Investor Relations ph: +46 733-666 599 paula.treutiger@meda.se

Meda AB discloses the information provided herein pursuant to the
Securities Markets Act and/or the Financial Instruments Trading Act.
The information was submitted for publication on April 4, 2014, at
15:00 CET.

MEDA AB (publ) is a leading international specialty pharma company.
Meda's products are sold in more than 120 countries worldwide and the
company is represented by its own organizations in over 55 countries.
The Meda share is listed under

Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find
out more, visit www.meda.se.

-----------------------------------------------------------
http://news.cision.com/meda/r/statement-by-the-board-of-directors-of-med...
http://mb.cision.com/Main/357/9564239/229511.pdf

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.